Claire Deligne
Postdoctoral Researcher
Tenascin-C is an extracellular matrix protein which is overexpressed during inflammatory diseases such as malignant cancers. In metastatic breast cancer in particular, the expression of high levels of tenascin-C is associated with a dramatic decrease of the patient’s survival.
My project consists in using cell biology technics and tumour models to decipher how tenascin-C impacts the differentiation, the prognosis value and the polarization of the adaptive immune response within the microenvironment of primary and metastatic tumours.
Recent publications
-
How to detect and purify tenascin-C.
Journal article
Giblin SP. et al, (2018), Methods Cell Biol, 143, 371 - 400
-
Impact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus?
Journal article
Deligne C. et al, (2017), Front Immunol, 8
-
Differential expression of interleukin-17 and interleukin-22 in inflamed and non-inflamed synovium from osteoarthritis patients.
Journal article
Deligne C. et al, (2015), Osteoarthritis Cartilage, 23, 1843 - 1852
-
Anti-CD20 therapy induces a memory Th1 response through the IFN-γ/IL-12 axis and prevents protumor regulatory T-cell expansion in mice.
Journal article
Deligne C. et al, (2015), Leukemia, 29, 947 - 957
-
[The Janus face of monoclonal antibodies in oncology: passive immunity and vaccination].
Journal article
Deligne C. and Teillaud J-L., (2013), Med Sci (Paris), 29, 57 - 63